BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11000062)

  • 41. [60 cases of advanced cancer treated by an association of ambulatory cytostatics during 1 to 4 years. Collaborational hospital consultation and doctors in charge of the cases].
    Israel L; Depierre A
    Therapeutique; 1970 Apr; 46(4):415-7. PubMed ID: 4987709
    [No Abstract]   [Full Text] [Related]  

  • 42. Biologic agents as modifiers of chemotherapeutic effects.
    Parmiani G; Rivoltini L
    Curr Opin Oncol; 1991 Dec; 3(6):1078-86. PubMed ID: 1843110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Control-relevant modeling in drug delivery.
    Parker RS; Doyle FJ
    Adv Drug Deliv Rev; 2001 Jun; 48(2-3):211-28. PubMed ID: 11369083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The use of biomodulators to potentiate chemotherapy in the treatment of cancer.
    Mitchell MS
    Cancer Invest; 1990; 8(2):279-80. PubMed ID: 2400947
    [No Abstract]   [Full Text] [Related]  

  • 45. Dose Finding Versus Speed in Seamless Immuno-Oncology Drug Development.
    Mayawala K; Tse A; Rubin EH; Jain L; de Alwis DP
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S143-S145. PubMed ID: 28921649
    [No Abstract]   [Full Text] [Related]  

  • 46. Cancer chemotherapeutic and biologic agents.
    Sadoff L
    CA Cancer J Clin; 1993; 43(2):127; author reply 127-8. PubMed ID: 8439810
    [No Abstract]   [Full Text] [Related]  

  • 47. [Trial in potentiation of antineoplastic effects].
    Yunoki K
    Nihon Rinsho; 1975 May; 33(5):1886-91. PubMed ID: 1171283
    [No Abstract]   [Full Text] [Related]  

  • 48. Multiphysics and Multiscale Analysis for Chemotherapeutic Drug.
    Zhang L; Kim SY; Kim D
    Biomed Res Int; 2015; 2015():493985. PubMed ID: 26491672
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Some approaches to the therapeutic exploitation of metabolic sites of vulnerability of neoplastic cells.
    Sartorelli AC
    Cancer Res; 1969 Dec; 29(12):2292-9. PubMed ID: 4905235
    [No Abstract]   [Full Text] [Related]  

  • 50. Controls in cancer chemotherapy.
    Kennedy BJ; Theologides A
    Ann Intern Med; 1972 Feb; 76(2):321-2. PubMed ID: 5009598
    [No Abstract]   [Full Text] [Related]  

  • 51. A simplified test for the independence of the joint action of two drugs.
    Schenzle D
    Biometrics; 1982 Mar; 38(1):275-6. PubMed ID: 7082760
    [No Abstract]   [Full Text] [Related]  

  • 52. Insulin potentiation therapy for cancer?
    Sissung TM; Schmidt KT; Figg WD
    Lancet Oncol; 2019 Feb; 20(2):191-192. PubMed ID: 30712796
    [No Abstract]   [Full Text] [Related]  

  • 53. What is synergy?
    Berenbaum MC
    Pharmacol Rev; 1989 Jun; 41(2):93-141. PubMed ID: 2692037
    [No Abstract]   [Full Text] [Related]  

  • 54. Introduction: the molecular cell biology of insulin production.
    Rhodes CJ
    Semin Cell Dev Biol; 2000 Aug; 11(4):223-5. PubMed ID: 10966855
    [No Abstract]   [Full Text] [Related]  

  • 55. [Insulin, eninsulin and cancer].
    BARRAL P
    Prog Med (Paris); 1947 Sep; 75(17):435. PubMed ID: 20271373
    [No Abstract]   [Full Text] [Related]  

  • 56. Nutraceuticals as Supportive Therapeutic Agents in Diabetes and Pancreatic Ductal Adenocarcinoma: A Systematic Review.
    Mikolaskova I; Crnogorac-Jurcevic T; Smolkova B; Hunakova L
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829437
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer.
    Klement RJ; Fink MK
    Oncogenesis; 2016 Feb; 5(2):e193. PubMed ID: 26878387
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modulation of insulin/IGFs pathways by sirtuin-7 inhibition in drug-induced chemoreistance.
    Aljada A; Saleh AM; Al Suwaidan S
    Diagn Pathol; 2014 May; 9():94. PubMed ID: 24885964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells.
    Volkova E; Robinson BA; Willis J; Currie MJ; Dachs GU
    Oncol Lett; 2014 Feb; 7(2):311-320. PubMed ID: 24396438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer.
    Damyanov C; Gerasimova D; Maslev I; Gavrilov V
    ISRN Urol; 2012; 2012():140182. PubMed ID: 22649741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.